Six challenges in the eradication of infectious diseases by Klepac, P et al.
SP
C
a
b
c
d
e
f
a
A
R
R
A
A
K
E
S
M
D
H
I
c
g
t
e
o
p
t
(
e
e
l
r
h
i
u
h
1Epidemics 10 (2015) 97–101
Contents lists available at ScienceDirect
Epidemics
j ourna l ho me  pa ge: www.elsev ier .com/ locate /ep idemics
ix  challenges  in  the  eradication  of  infectious  diseases
etra  Klepaca,∗,  Sebastian  Funkb, T.  Deirdre  Hollingsworthc,d,
. Jessica  E.  Metcalf e, Katie  Hampsonf
Department of Applied Mathematics and Theoretical Physics, Cambridge University, Cambridge, UK
Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK
Mathematics Institute and the School of Life Sciences, University of Warwick, UK
Liverpool School of Tropical Medicine, UK
Department of Ecology and Evolutionary Biology and the Woodrow Wilson School, Princeton University, Princeton, NJ, USA
Boyd Orr Centre for Population and Ecosystem Health, University of Glasgow, UK
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 3 March 2014
eceived in revised form 3 December 2014
ccepted 4 December 2014
vailable online 12 December 2014
a  b  s  t  r  a  c  t
Eradication  and  elimination  are  increasingly  a part of  the  global  health  agenda.  Once  control  measures
have  driven  infection  to  low  levels,  the  ecology  of  disease  may  change  posing  challenges  for  eradication
efforts.  These  challenges  vary  from  identifying  pockets  of  susceptibles,  improving  monitoring  during  and
after  the  endgame,  to  quantifying  the economics  of  disease  eradication  versus  sustained  control,  all  of
which  are  shaped  and  inﬂuenced  by processes  of loss  of immunity,  susceptible  build-up,  emergence  ofeywords:
limination
urveillance
odelling
ynamics
eterogeneity
resistance,  population  heterogeneities  and non-compliance  with  control  measures.  Here  we  discuss  how
modelling  can  be used  to address  these  challenges.
©  2014  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).ntroduction
Only two  diseases, smallpox and rinderpest, have been eradi-
ated. Yet eradication is increasingly part of the language of the
lobal health community. Calls have been made for the eradica-
ion of diseases as diverse as guinea worm and malaria. While
ach disease poses a unique set of issues, there are a number
f recurring challenges that emerge during the endgame, or the
hase during which control efforts are intensiﬁed and targeted
owards achieving elimination locally and eradication globally
see Fig. 1 for a visualization of different control stages towards
limination).
In order to be successful, eradication effort has to permanently
liminate a pathogen everywhere in the world; pathogen preva-
ence is globally reduced to zero, thereby removing the risk of
e-introduction and re-establishment. Elimination, on the other
and, is a more localized effort that focuses on reduction to zero
ncidence of a certain pathogen in a given area, with active meas-
res to prevent pathogen re-establishment from other areas after
∗ Corresponding author.
E-mail address: pklepac@alum.mit.edu (P. Klepac).
ttp://dx.doi.org/10.1016/j.epidem.2014.12.001
755-4365/© 2014 The Authors. Published by Elsevier B.V. This is an open access article unelimination. Since eradication is elimination on global scale, there
are many similarities between those two  efforts, particularly in
dynamical transitions from endemic transmission to elimination
and post-elimination period of enhanced vigilance (see Fig. 1). Once
infection is driven to very low levels, the ecology of pathogens
may  change requiring different surveillance and control strategies.
Susceptible build-up, waning of immunity, increase in the age of
infection, non-compliance of individuals with control measures,
pathogen change and emergence of resistance as a result of inten-
siﬁed efforts all become increasingly important during the ﬁnal
stages of eradication programmes. This calls for the development
of a research agenda for epidemiological modellers that directly
addresses these challenges, from the design of models to target
control strategies, to the optimization of surveillance and deter-
mining data needs to address, amongst others, the questions we
outline below.
In addition to visualizing stages of elimination and correspond-
ing reduction in disease prevalence and change in dynamical
regime, Fig. 1 also serves as a timeline of eradication efforts that
we use to structure the rest of this manuscript. Before eradication
efforts are attempted, is there a way  to estimate how likely are they
to succeed and how much they are going to cost compared to sus-
tained control? Is there a way to quantify the susceptible landscape
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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hat will improve targeting of efforts and monitoring strategies in
he pre-elimination and elimination phase?
. Provide a systematic framework for when we  should try
o eradicate
Eradication of infectious diseases is a vast public health, political
nd economic commitment and the intensity of efforts needed to
liminate a disease cannot be sustained indeﬁnitely. The costs and
isks are high, as are the potential beneﬁts. During the dynamic
ransition from endemic transmission to local elimination (Fig. 1)
otential shifts in age at ﬁrst infection, waning of immunity, suscep-
ible build-up, emergence of resistance, etc. can lead to dynamical
eedbacks and logistical challenges that can cause unanticipated
ifﬁculties for eradication. For emerging infections, modelling
athogen properties demonstrated how timing of infectiousness
nd appearance of symptoms determines the likely success of iso-
ating infectious individuals and their contacts in controlling an
utbreak (Fraser et al., 2004). An analogous framework that can
dentify what makes a disease “easy” vs. “hard” to eradicate would
e a ﬁrst step in providing a mechanism of prioritizing efforts and
trategies.
Such a framework needs to include processes that shape
nfectious disease dynamics but that operate on very different
ime scales. For example, intensive efforts exert strong selec-
ive pressures on the pathogen and prolonging the elimination
hase (Fig. 1) increases the probability of emergence of anti-
icrobial or insecticide resistance, vaccine escape or antigenic
ivergence, potentially creating novel problems. While the evo-
utionary timescales over which drugs fail due to resistance
re affected by application strategies or drug regimens, replen-
shment of susceptible populations and ageing of “naturally
mmunised” cohorts occur on demographic time-scales deter-
ined by turnover, which varies drastically across populations.
odels can help identify key-time scales for eradication, how
hey vary for different pathogens, and how long can intensiﬁed
limination efforts be sustained, without detrimental conse-
uences.
Biological feasibility of eradication depends, among other fac-
ors, on the pathogen lifecycle, its reservoirs, persistence in the
nvironment, clinical manifestations of disease, sensitivity and
peciﬁcity of laboratory tests to conﬁrm the disease as well as safe
nd effective control measures. A related biological factor is the
resence of related pathogens that might take advantage of a niche
acated by eradication (Lloyd-Smith, 2013). Although crucial, bio-
ogical factors are not the only prerequisites – logistic, operational,
olitical and socioeconomic factors are all critical in determining
Control phase Pre-eliminaonphase
Endemic transmission,
control in place to reduce
number of cases
Endemic transmission
interrupted,
large outbreaks sll
possible
R ≈ 1 R > 1 
detected
cases
ig. 1. Stages towards and after elimination in a given location and milestones on the path
007). Shading illustrates control intensity (darker grey for heightened efforts). 10 (2015) 97–101
whether or not eradication can be achieved and should be incorpo-
rated into models.
2. Develop quantitative models of the economics of control
versus eradication
Cost-effectiveness of control methods is increasingly a deciding
factor in their implementation (Jit et al., 2008; Baguelin et al., 2012).
The reasons for this are fairly intuitive, as it is rational not to attempt
something unless the beneﬁts of that action exceed the costs. Yet
it can be difﬁcult to accurately estimate costs of control efforts and
their beneﬁts when eradication is one of several options. Should
we aim for long-term control, tolerating a certain level of infection,
or should we push for eradication? When is one option preferable
and what kind of models do we need to help distinguish between
the two?
Analysis of costs is hard even retrospectively, but estimating
these costs in advance is even more challenging. There are several
reasons for this. First, costs of expanding control efforts increase; for
example, the last foci of infection, or pockets of susceptibility will
be those that are hardest to reach, either geographically or socially
(e.g. vaccine refusers). The challenge for modelling is to accurately
tie the economics of scaling up control programmes with the epi-
demiology and changing ecology of the disease (Klepac et al., 2011).
Second, control efforts are implemented within health systems
very differently from eradication efforts. Control programmes are
usually integrated in horizontal programmes focused on strength-
ening primary care and providing ‘health for all’ (Aylward et al.,
1998). Elimination and eradication efforts on the other hand often
require a targeted ‘vertical approach,’ sometimes at the expense
of other public health issues. But elimination efforts can also
strengthen primary healthcare by providing basic services and
improving surveillance (yaws), training personnel and expand-
ing immunization programmes (smallpox), or establishing a global
laboratory network (polio) (Klepac et al., 2013). The impacts on
health systems of such secondary or intangible beneﬁts of elim-
ination programmes are particularly hard to measure (Closser
et al., 2012), posing a challenge of how to integrate them into
models.
Expansion of efforts is very costly and prolonging the endgame
leads to donor fatigue risking re-emergence if efforts are scaled-
down prematurely. Prolonged low incidence levels during the
epidemic tail (as illustrated by the low number of cases in the
elimination phase in Fig. 1) can also lead to disengagement of
communities with eradication efforts, complacency and ‘individ-
ual fatigue’ or even active refusal of vaccination (Saint-Victor and
Omer, 2013). In addition, a prolonged epidemic tail may contribute
Eliminaon phase Post-eliminaonphase
Localised outbreaks
related to
importaons
me
Regional or worldwide
(in case of eradicaon) 
incidence low, focus on 
prevenon of reintroducon
R < 1 
 to elimination. Adapted from (Townsend et al., 2013b; World Health Organization,
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o seeding outbreaks elsewhere (O’Reilly et al., 2011), escalating
he costs and jeopardizing chances of success.
For many diseases, the probability of severe complications and
he costs of treatment vary with patient age. Population ageing
ill therefore also affect the costs of control and elimination pro-
rammes. The impacts of changing demography might be more
ostly for sustained, long-term control efforts than for intense, but
ime-limited eradication programmes which might be a new argu-
ent for eradication. Models that consider epidemic, economic
nd demographic detail on an appropriate time-scale will help
nswer these questions. Estimates of disease burden that incor-
orate dynamical effects of control efforts (e.g. Simons et al., 2012)
rovide a promising avenue for quantifying these costs and bene-
ts.
Finally, in some circumstances, projected costs may  suggest that
radication is not feasible. Given that some of the beneﬁts of eradi-
ation are difﬁcult or impossible to express in monetary terms (e.g.
mproving the vaccine supply chain may  enable easier and cheaper
istribution of future antigens; possible non-linear interactions
ith other pathogens), ﬁnancial reasoning and cost-effectiveness
ay  not be the only reasoning to guide elimination efforts (Sabot
t al., 2010). Can modelling approaches offer alternatives that take
s beyond cost-effectiveness? Developing consistent metrics of
ealth beneﬁts would make it easier to measure total direct and
ndirect beneﬁts of implemented efforts and improve economic
valuations used to inform public health decisions.
. Identify the most effective approaches to achieve
radication
The dynamics of infectious diseases close to elimination can be
istinctly different from natural dynamics (Fig. 1). The distribu-
ion of susceptibility is no longer governed by a combination of
eplenishment of the susceptible population through births, and
mmunity through past exposure but, instead, by vaccination cov-
rage, the extent of mass drug administrations (in the case of many
ampaigns against NTDs (Bockarie et al., 2013)) or behavioural
hanges (e.g. guinea worm that is on track to be eliminated without
he use of drug or vaccine (Biswas et al., 2013; Barry, 2007)). These
nterventions introduce an element of heterogeneity, which can
ffect infection dynamics. If those susceptible (e.g., unvaccinated)
re preferentially in contact with each other because of geographi-
al and/or social proximity, there is a risk of large outbreaks, which
an be hard to predict because introductions into those populations
ight be rare.
Models need to be designed to take into account these dynami-
al transitions and predict where and when outbreaks are at most
isk of occurring, as well as suggest appropriate prevention and
ntervention strategies. Using outbreak data from England and
ales, Jansen and colleagues (Jansen et al., 2003) showed that
hile measles transmission in the UK remained subcritical (locally
liminated with short-lived outbreaks from imported infections)
he reproductive number, R, signiﬁcantly increased in the wake of
eclining vaccination coverage, suggesting that continued low vac-
ine uptake could lead to re-establishment of endemic measles.
imilar branching process models may  have utility for identify-
ng pivotal dynamics during the endgame. Additionally, endgame
ynamics should be reconsidered in the light of a heterogeneous
andscape of susceptibility and stochastic fade-outs to inform how
uch control is needed to drive an infection to extinction and, con-
equently, how to best allocate the resources in eradication efforts.
Approaches during the endgame often differ from sustained,
ess intense control during the ‘middle game’ (Fig. 1). The small-
ox effort switched from mass vaccination campaigns to repetitive
ctive searches conducted by a massive army of health personnel 10 (2015) 97–101 99
going door-to-door to look for any last remaining cases. Mod-
elling work and statistical inference from polio surveillance data
identiﬁed the value of switching to a more immunologically
effective monovalent vaccine (Grassly et al., 2006) prompting a
substantial investment in vaccine development. India was recently
certiﬁed free from polio, resulting from this switch (WHO, 2014).
Using models to assess the limitations of conventional control
measures in the face of shifting dynamics, and identifying strategies
that increase the probability of eliminating infection, such as the
optimal time to intensify efforts or switch strategies, could reduce
the length of the epidemic tail (such as in polio).
4. Quantify the landscape of susceptibility
For immunizing (or partially-immunizing) infections, the age,
location and social grouping of individuals that remain susceptible
as incidence declines to low levels, will be the key determinant of
progress towards elimination. The main data-stream available for
evaluating this landscape of susceptibility is often surveillance for
cases or deaths – susceptibility itself is generally a hidden variable.
For completely immunizing infections, susceptible reconstruction
can provide some insight into the dynamics of immunity – but infer-
ence is weakened speciﬁcally where the risk of infection is low (i.e.,
in an elimination context), since the assumption that everyone can
acquire the infection no longer holds.
Expanding the statistical and modelling toolset available for
inferring the temporal, geographic, or social patterns of suscepti-
bility is a key challenge in using modelling to support elimination
or eradication efforts. This effort will likely include development of
models that can synthesize diverse sources of information encom-
passing serological surveys, coverage estimates, and demographic
rates among others. Quantitative descriptions of past dynamics of
the population via these variables will inform the likely current
proportion of susceptible individuals, their ages, and geographic
locations. The history of outbreaks will be an important piece in
this puzzle – a large outbreak or campaign could deplete suscep-
tibles such that a long interval without infection (‘honey-moon
period’ (McLean and Anderson, 1988)) results; and can be followed
by a large, late age outbreak (observed during the recent measles
outbreak in Swansea (Wise, 2013)).
Amongst these various data-streams, serological surveys supply
perhaps the most direct measure of susceptibility. Nevertheless,
there are considerable open challenges in the analyses of serologi-
cal data. For many infections, vaccine and natural immunity cannot
currently be distinguished. Ideally, clinical measures of serology
could be improved to allow this, but in the absence of such progress,
models that build around other known variables (past outbreak
sizes, coverage estimates, etc.) may  be able to generate inference
to distinguish vaccine coverage from natural immunity. This will
allow detection of whether the disease is still circulating in cer-
tain populations or spilling over from nearby reservoirs (crucial for
diseases such as rinderpest and FMD  where premature cessation of
vaccination can lead to costly resurgence). More generally, much of
the data collected as part of a serological survey is often jettisoned
in analyses – in particular, continuous titres are translated into dis-
crete positive/negative variables. Data on the continuum of titre
values might be leveraged to infer levels, or recency of exposure
via models that incorporate epidemiological data.
As we  address increasingly complex pathogens, which may
ﬂuctuate in their characteristics over time, space and severity of
infections (e.g. malaria, where low immunity is linked to more
severe infections (Snow et al., 1997)) such modelling innovations
that yield deeper insight into the biology may  be key. Furthermore,
they may  contribute to identifying if and when pathogen escape
from chemotherapy or vaccination is occurring. Finally, a challenge
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s developing models capable of forecasting the likely consequences
f an elimination programme were to fail (for example, (Townsend
t al., 2013a)).
. Improve monitoring during and after the endgame
Once a disease is close to elimination locally, the few remaining
ases may  be concentrated in hard-to-reach groups, for social,
ogistical or geographic reasons; may  be predominantly asymp-
omatic cases; and may  be temporally very irregular. Following
limination, new outbreaks may  develop rapidly and be detected
hrough clusters of severe cases, or may  develop more slowly and
e detected though serological studies. As immunity shifts in the
opulation following elimination, the age-distribution or charac-
eristics of cases may  also shift. The question of how to design the
ight surveillance strategy to assist the drive towards elimination,
o conﬁrm that elimination has been achieved and to assist in pre-
enting re-emergence all require a detailed understanding of the
haracteristics of the disease and its dynamics (see (Woolhouse,
013)). A classic problem in elimination and re-emergence is that
assive surveillance may  only capture the ‘tip of the iceberg’ –
ormally the symptomatic cases or those that are laboratory con-
rmed (Townsend et al., 2013b). Responses based on only these
ases may  be delayed relative to the outbreak. Either new diag-
ostics are needed to identify and treat asymptomatic cases (e.g.
isceral leishmaniasis (Guerin et al., 2002)), or responses need to
ake into account the likely pool of infectives around an identiﬁed
ase (the ratio of infections to reported cases). If the dynamics of
he disease are such that there are hotspots of infection, this may
ake a spatial response a very effective tool.
In addition to the challenge of designing the right surveil-
ance method epidemiologically, there are challenges around
nterpreting existing surveillance data, or designing new surveil-
ance strategies that are logistically feasible. This includes not
nly monitoring of disease but also of control processes, such
s drug distribution, bed net usage (rather than distribution)
nd systematic uptake or refusal of vaccines (e.g. (Lessler et al.,
011)).
A  further complication in designing surveillance is accounting
or spatial coupling (e.g. (Metcalf et al., 2013)) and interconnect-
dness of areas at different stages of elimination. For example, as
art of a feasibility study of malaria elimination in Zanzibar, mobile
hone movement data suggested that travel from mainland Tan-
ania was so intense that local controls alone would be unlikely to
liminate malaria due to high rates of importation (Tatem et al.,
009).
. Identify post-eradication opportunities and threats
Finally, in the event of successful elimination/eradication how
ong do we need to hold the line? Should one invest in maintaining
erd immunity, or implement low-level indeﬁnite control, or stop
ith the efforts altogether (as with smallpox)? If we were to scale
own or stop control efforts, when would it be safe to do so (see
Townsend et al., 2013b))? Should we switch to a different strategy
nd, if so, when? What are the spatial strategies for maintaining
reedom from disease? What deﬁnes the width of a protective cor-
on sanitaire and how should elimination efforts be coordinated
cross international boundaries?
Models that estimate or account for spatial coupling could guide
patial strategies, to minimize re-introductions from endemic
reas (through coordinated efforts) and maintain disease freedom
through for example the design of cordon sanitaires). Finally, mod-
ls should be able to provide guidance on whether eradication 10 (2015) 97–101
has been achieved, by informing estimates of the proportion of
cases detected for a given surveillance programme (Townsend et al.,
2013b).
Detection of low-level infection requires ever more sensitive
and more accurate detection methods, so surveillance abilities
are crucial in post-eradication strategies. Measuring loss of herd
immunity or ﬁnding asymptomatic carriers might require new
surveillance and monitoring techniques and better statistical tools
in analysis of the relevant data. All of these need to be considered
in a dynamical framework to predict possible shifts in dynamical
regimes or potential tipping points for re-emergence of elimi-
nated pathogens or emergence of related ones through competitive
release in vacated niches (Lloyd-Smith, 2013).
Conclusions
Eradication initiatives require sustained public health, politi-
cal, ﬁnancial and individual efforts. It is a dynamical challenge
that requires vast data integration over temporal, geographical and
socioeconomic scales. Yet the inherently dynamic nature of infec-
tious diseases can also have unexpected advantages. Even though
the malaria eradication programme in the 1950s failed, a number
of successful countries have remained malaria free (Smith et al.,
2013). Models demonstrated malaria elimination to be a surpris-
ingly stable state (Smith et al., 2013), indicating that elimination
could be incrementally achieved without needing the simultaneous
and correspondingly expensive effort as required for say polio. The
eradication endgame poses a diverse set of challenges that can be
addressed in a modelling framework leading to improved surveil-
lance and control.
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